8-K: Silexion Therapeutics Presents Promising Data on SIL204 for KRAS-Driven Cancers

Silexion Therapeutics has released a corporate presentation highlighting the potential of its SIL204 siRNA therapy for treating KRAS-driven cancers, particularly pancreatic cancer, with plans to initiate a Phase 2/3 trial in 2026.

Summary

• Silexion Therapeutics is developing RNAi therapeutics to silence oncogenes, focusing on KRAS mutations that drive cancer growth.
• Their lead candidate, SIL204, is an optimized siRNA designed to target KRAS G12D/V mutations, which are prevalent in pancreatic, colorectal, and lung cancers.
• A Phase 2 trial of their first-generation siRNA, LODER, in locally advanced pancreatic cancer (LAPC) showed a trend for a 9.3-month improvement in overall survival when combined with chemotherapy compared to chemotherapy alone.
• SIL204 is designed to be more stable and have broader activity than LODER, with potential for pan-KRASG12x activity.
• Preclinical studies of SIL204 have demonstrated significant tumor growth inhibition and increased tumor necrosis in mice.
• The company plans to submit a Clinical Trial Application (CTA) in the EU in the first half of 2026 and initiate a Phase 2/3 trial for SIL204 in LAPC in the same period.
• Silexion has a strong intellectual property portfolio with patents extending to 2043 and beyond.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical data and a clear development plan for SIL204. The company's innovative approach and strong IP portfolio contribute to a favorable sentiment, although the early stage of development and lack of revenue generation temper the enthusiasm.

Positives

• The company's siRNA platform targets the root cause of cancer by silencing oncogenes.
• The Phase 2 trial of LODER showed a significant improvement in overall survival for patients with LAPC.
• SIL204 has demonstrated enhanced stability and broader activity compared to the first-generation siRNA.
• Preclinical data for SIL204 shows promising results in tumor growth inhibition and necrosis.
• Silexion has a clear regulatory path forward with guidance from the German Federal Institute for Drugs and Medical Devices (BfArM).
• The company has a strong intellectual property portfolio with patents extending to 2043 and beyond.
• SIL204 has potential for pan-KRASG12x activity, covering a broader range of KRAS mutations.

Negatives

• Silexion is a development-stage company with a limited operating history.
• The company has not generated any revenue from product sales and may never be profitable.
• The approach Silexion is taking to develop RNAi therapeutics is unproven for oncology.
• There is uncertainty regarding market receptiveness to their product candidates and insurance coverage.
• The company may face challenges in attracting and retaining key personnel.
• The Phase 2 trial of LODER had some serious adverse events related to the treatment and administration procedure.

Risks

• Silexion is a development-stage company and has a limited operating history.
• The company has never generated any revenue from product sales and may never be profitable.
• The approach Silexion is taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
• Silexion does not have experience producing its product candidates at commercial levels, currently has no marketing and sales organization, has an uncertain market receptiveness to its product candidates, and is uncertain as to whether there will be insurance coverage and reimbursement for its potential products.
• Silexion may be unable to attract, develop and/or retain its key personnel or additional employees required for its development and future success.
• The Phase 2 trial of LODER had some serious adverse events related to the treatment and administration procedure.

Future Outlook

Silexion plans to advance SIL204 into a Phase 2/3 clinical trial in the EU in the first half of 2026, with a focus on locally advanced pancreatic cancer. They also plan to submit an IND to the FDA to expand the trial to the US.

Management Comments

• The company is focused on developing innovative treatments for KRAS-driven cancers.
• Silexion is leveraging the clinical data from the LODER trial to further improve the efficacy and safety of SIL204.

Industry Context

The development of targeted therapies for KRAS-driven cancers is a significant area of focus in oncology, as KRAS mutations are common in many types of cancer. Silexion's approach of using RNAi to silence oncogenes at the gene expression level is a novel approach compared to traditional small molecule inhibitors.

Comparison to Industry Standards

• Silexion's approach of using siRNA to target KRAS mutations differs from companies like Amgen and Mirati Therapeutics, which focus on small molecule inhibitors targeting the KRAS G12C mutation.
• The 9.3-month overall survival improvement observed with LODER in LAPC is a promising result compared to historical data for chemotherapy alone, but further data from the SIL204 trial will be needed to confirm these results.
• The stability and broad activity of SIL204 appear to be an improvement over previous siRNA therapies, potentially addressing limitations of earlier approaches.
• The company's focus on intratumoral delivery via endoscopy is a unique approach compared to systemic delivery of small molecule inhibitors.

Stakeholder Impact

• Shareholders may benefit from the potential success of SIL204 and the company's growth.
• Patients with KRAS-driven cancers may have access to a new treatment option.
• Employees may have opportunities for growth and development within the company.
• The company's success could lead to partnerships with suppliers and other stakeholders.

Next Steps

• Submit a Clinical Trial Application (CTA) in the EU for a Phase 2/3 trial of SIL204 in LAPC.
• Initiate a Phase 2/3 clinical trial of SIL204 in LAPC in Germany and Israel.
• Submit an Investigational New Drug (IND) application to the FDA to expand the Phase 2/3 trial to the US.
• Continue GMP production of SIL204 for clinical trials.

Key Dates

Keywords

siRNA, KRAS, oncogene, pancreatic cancer, SIL204, LODER, RNAi, cancer therapy, clinical trial, targeted delivery